Wyatt Shields receives Grubstake Award to advance treatment toward clinical use
Assistant Professor Wyatt Shields
High-grade serous carcinoma is the deadliest form of ovarian cancer, and while a drug called olaparib can help prevent the cancer from returning, it often causes serious side effects. To address this challenge, Wyatt Shields, assistant professor in ¶¶ÒõÂÃÐÐÉä Boulder’s Department of Chemical and Biological Engineering, ÌýBenjamin Bitler, associate professor in the ¶¶ÒõÂÃÐÐÉä Anschutz Division of Reproductive Sciences and ¶¶ÒõÂÃÐÐÉä PhD Student Courtney Bailey have developed a new way to deliver the drug more safely. Their approach uses tiny, biodegradable particles carried by immune cells to deliver treatment directly to tumors, helping reduce harmful effects on the rest of the body. Funding totaling $300,000 from the at , in partnership with , will support the next steps to move this technology closer to clinical use.
Read more at